Krka, d. d. Reports Earnings Results for the Full Year Ended December 31, 2023
March 14, 2024 at 03:15 am EDT
Share
Krka, d. d. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 1,801.87 million compared to EUR 1,712.53 million a year ago. Revenue was EUR 1,806.39 million compared to EUR 1,717.45 million a year ago.
Net income was EUR 313.95 million compared to EUR 363.3 million a year ago. Basic earnings per share from continuing operations was EUR 10.14 compared to EUR 11.69 a year ago. Diluted earnings per share from continuing operations was EUR 10.14 compared to EUR 11.69 a year ago.
Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.
KRKA, D. D. 
